Skip to content

The Full Story: Why Was Sweetener 952 Banned?

4 min read

In 1969, the U.S. Food and Drug Administration (FDA) controversially banned the artificial sweetener known as cyclamate, also designated as sweetener 952, following animal studies that suggested a link to cancer. This decision sparked decades of debate and research, with many countries later reaching different safety conclusions.

Quick Summary

An exploration of why sweetener 952 (cyclamate) was banned in the U.S. in 1969, triggered by controversial rat studies. The ban's origin, the subsequent scientific findings refuting the cancer link, and its contrasting legal status globally are examined.

Key Points

  • Initial US Ban: Sweetener 952 (cyclamate) was banned in the US in 1969 by the FDA based on a controversial study linking it to bladder cancer in rats.

  • Refuted Cancer Link: Later scientific studies largely refuted the initial cancer findings, highlighting flaws in the original research, which involved excessively high doses and a saccharin mixture.

  • Global Status Discrepancy: While the ban persists in the US, cyclamate is approved and widely used in many other countries, including the European Union and Canada.

  • Cyclohexylamine Metabolite: Concerns were also raised over cyclohexylamine, a metabolite of cyclamate, which caused testicular atrophy in rats, though the relevance to humans remains debated.

  • Enduring U.S. Regulation: The ban's longevity in the U.S. is attributed to a combination of bureaucratic inertia, regulatory complexities, and the financial hurdles of petitioning for re-approval.

  • Modern Context: International bodies like WHO have issued general warnings on artificial sweetener use for long-term weight control, but this is separate from the initial, specific carcinogenic concerns regarding cyclamate.

In This Article

The Controversial 1969 Ban in the United States

The story of sweetener 952, or cyclamate, began with an unexpected discovery in 1937 but came to a dramatic halt in the United States decades later. Cyclamate was widely used in diet foods and drinks throughout the 1950s and 60s, offering a zero-calorie alternative to sugar. However, the product's fate in the U.S. was sealed in 1969 after controversial animal research emerged.

Following a laboratory study where a 10:1 mixture of cyclamate and saccharin led to bladder tumors in rats, the FDA took swift action. This decision was heavily influenced by the Delaney Clause of the 1958 Food Additives Amendment, which mandated that any food additive shown to cause cancer in animals or humans be banned. Despite the fact that the study involved a mix of sweeteners at extremely high doses, the FDA's decision effectively removed cyclamate from the American market.

The ban sent shockwaves through the food and beverage industry, leading to massive product recalls and reformulations. Manufacturers were left scrambling to find an alternative sweetener, with many temporarily switching back to saccharin, a move that would also later face its own safety questions.

The Aftermath: Contradictory Findings and Scientific Scrutiny

Following the 1969 ban, extensive research was conducted to re-evaluate cyclamate's safety. These subsequent studies painted a much more complex picture and largely failed to reproduce the initial carcinogenic findings. Here are some of the key scientific developments:

  • Refuted Carcinogenicity: The initial animal studies, criticized for their design and the excessively high doses used, were later challenged. A 1984 review by the FDA's own Cancer Assessment Committee concluded that cyclamate was not carcinogenic.
  • Testicular Atrophy Concern: Another area of investigation focused on cyclohexylamine, a metabolite of cyclamate produced by gut bacteria in some individuals. Studies showed that high doses of cyclohexylamine could cause testicular atrophy in rats. However, this effect was not observed in other species, and the doses required were far beyond typical human consumption levels.
  • Global Re-evaluations: Many international regulatory bodies, such as the European Food Safety Authority (EFSA), the Joint FAO/WHO Expert Committee on Food Additives (JECFA), and Food Standards Australia New Zealand (FSANZ), conducted their own re-evaluations. They concluded that cyclamate was safe for human consumption within specified acceptable daily intake (ADI) levels.

The Lingering U.S. Ban

Despite decades of scientific evidence refuting the original cancer link, the ban in the United States remains in place. This persistence is often attributed to bureaucratic inertia and the high financial cost of petitioning the FDA for re-approval. A petition to reverse the ban was submitted but has been held in abeyance, preventing its active consideration. The differing regulatory stances highlight a significant divergence in how countries weigh scientific evidence and historical data.

Global Regulatory Status: A Comparison

The legal status of sweetener 952 varies drastically around the world. Below is a comparison of its status in a few key regions, illustrating the differences in regulatory approaches:

Feature United States (FDA) European Union (EFSA) Australia & New Zealand (FSANZ)
Current Status Banned for general food use. Approved as a food additive (E952). Approved as a food additive (INS 952).
Initial Ban 1969, based on disputed rat studies. Was temporarily banned in the UK, but approved in 1996. Temporarily restricted, but approval was later lifted.
Reason for Ban Initial, controversial findings of potential carcinogenicity. Concerns were later refuted and product was re-evaluated as safe. Concerns were later refuted and product was re-evaluated as safe.
Acceptable Daily Intake (ADI) Not applicable. 7 mg per kg of body weight. Deemed safe within established limits.
Key Differences Ban remains largely due to regulatory framework and inertia, not modern scientific consensus. Regulatory system allows for re-evaluation based on updated science. Similar to the EU, safety is reviewed based on recent scientific data.

Conclusion: A Ban Defined by History, Not Consensus

The story of why sweetener 952 was banned is a classic case of scientific misunderstanding and regulatory overreach that has created a lasting legacy. While the initial animal studies caused a legitimate scare in the 1960s, subsequent research has overwhelmingly failed to support the claim that cyclamate poses a cancer risk to humans at normal consumption levels. The current discrepancy between the U.S. and many other developed nations demonstrates how historical decisions can endure long after the original evidence has been discredited. Today, cyclamate is still a legal and widely-used sweetener in dozens of countries, while in the U.S., the ban continues to highlight the complexities of food safety regulation and the difficulty of reversing past decisions. For more detailed toxicological analysis of cyclamates, see the National Institutes of Health (NIH) study.

Frequently Asked Questions

Sweetener 952 is the food additive code for cyclamate, an artificial, non-caloric sweetener discovered in 1937. It is 30-50 times sweeter than sugar and is often used in combination with other sweeteners.

The FDA banned sweetener 952 in 1969 after a study involving rats fed a cyclamate-saccharin mixture at very high doses showed an increased incidence of bladder tumors.

Yes, despite subsequent studies refuting the initial cancer findings, cyclamate remains banned for general food use in the United States.

Yes, cyclamate is approved as a food additive and considered safe for consumption within established limits in over 50 countries, including the European Union, Canada, and Australia.

No. Subsequent reviews of the evidence, including by scientific panels and international health organizations, have concluded that cyclamate is not carcinogenic to humans.

Cyclohexylamine is a metabolite of cyclamate created by gut bacteria in some people. While high doses caused testicular atrophy in rats, the effect was species-specific, and the doses were not relevant to human exposure.

The ban has not been reversed due to a combination of legal requirements, bureaucratic hurdles, and the high cost of resubmitting a petition to the FDA for re-approval.

References

  1. 1
  2. 2
  3. 3
  4. 4

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.